Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: A systematic review and meta-analysis

Ultrasound in Obstetrics and Gynecology

Volumn 45, Issue 1, 2015, Pages 16-26

  Akolekar, R ^a,b   Beta, J ^a   Picciarelli, G ^a   Ogilvie, C ^c   D'Antonio, F ^d  

^a MEDWAY MARITIME HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Amniocentesis; Chorionic villus sampling; CVS; Fetal loss; Invasive diagnostic procedure; Miscarriage; Pregnancy loss; Prenatal diagnosis; Procedure related loss

Indexed keywords

ABORTION, SPONTANEOUS; ADVERSE EFFECTS; AMNIOCENTESIS; ANEUPLOIDY; CHORION VILLUS SAMPLING; DECISION MAKING; FEMALE; GESTATIONAL AGE; HUMAN; META ANALYSIS; PATIENT EDUCATION; PREGNANCY; PRENATAL DIAGNOSIS; RISK; RISK FACTOR;

ABORTION, SPONTANEOUS; AMNIOCENTESIS; ANEUPLOIDY; CHORIONIC VILLI SAMPLING; DECISION MAKING; FEMALE; GESTATIONAL AGE; HUMANS; ODDS RATIO; PATIENT EDUCATION AS TOPIC; PREGNANCY; PRENATAL DIAGNOSIS; RISK FACTORS;

EID: 84920848763     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.14636     Document Type: Article

References (60)

1. Amniocentesis information for parents and chorionic villus sampling (CVS) information for parents. http://fetalanomaly.screening.nhs.uk/leafletsforparents. [Accessed 1 March 2014].
2. Royal College of Obstetricians and Gynaecologists (RCOG). Amniocentesis and Chorionic Villus Sampling. Green Top Guideline No.8. RCOG Press: London, 2010.
3. Royal College of Obstetricians and Gynaecologists (RCOG). Chorionic villus sampling and amniocentesis - Information for you. RCOG Press: London, September 2011. http://www.rcog.org.uk/womens-health/clinical-guidance/amniocentesis-chorionic-villus-sampling-cvs-what-you-need-know [Accessed 1 March 2014].
4. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007; 110: 1459-1467.
5. Wilson RD, Langlois S, Johnson JA; Society of Obstetricians and Gynaecologists of Canada. Mid-trimester amniocentesis fetal loss rate. J Obstet Gynaecol Can 2007; 29: 586-595.
6. Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110: 687-694.
7. Ogilvie CM, Akolekar R. Procedure-related pregnancy loss following invasive prenatal sampling: time for a new approach to risk assessment and counselling. Expert Rev Obstet Gynecol 2013; 8: 135-142.
8. Turhan NO, Eren U, Seckin NC. Second-trimester genetic amniocentesis: 5-year experience. Arch Gynecol Obstet 2005; 271: 19-21.
9. Caughey AB, Hopkins LM, Norton ME. Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. Obstet Gynecol 2006; 108: 612-616.
10. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH. Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 2009; 34: 14-18.
11. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
12. Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, Lun FM, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011; 342: c7401.
13. Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Fetal Diagn Ther 2014; 35: 156-173.
14. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, Guyatt G, Devereaux PJ, Thabane L. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLoS One 2011; 6: e25491.
15. Survival of extremely preterm infants: Joint statement from the British Medical Association, the British Association of Perinatal Medicine, the Faculty of Sexual and Reproductive Healthcare, the Royal College of Nursing and the Royal College of Obstetricians and Gynaecologists. http://www.rcog.org.uk/files/rcog-corp/uploaded-files/JointStatementBMABAPMFSRHRCNRCOG24wkMay08.pdf. [Accessed 1 March 2014].
16. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalysis. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp [Accessed 3 March 2014].
17. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
19. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
21. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org [Accessed 8 March 2014].
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
23. Muller F, Thibaud D, Poloce F, Gelineau MC, Bernard M, Brochet C, Millet C, Réal JY, Dommergues M. Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers. Prenat Diagn 2002; 22: 1036-1039.
24. Centini G, Rosignoli L, Kenanidis A, Scarinci R, Petraglia F. A report of early (13 + 0 to 14 + 6weeks) and mid-trimester amniocenteses: 10 years' experience. J Matern Fetal Neonatal Med 2003; 14: 113-117.
25. Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, Porter TF, Luthy DA, Comstock CH, Saade GR, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006; 108: 1067-1072.
26. Kong CW, Leung TN, Leung TY, Chan LW, Sahota DS, Fung TY, Lau TK. Risk factors for procedure-related fetal losses after mid-trimester genetic amniocentesis. Prenat Diagn 2006; 26: 925-930.
27. Mazza V, Pati M, Bertucci E, Re C, Ranzi A, Percesepe A, Forabosco A, Volpe A. Age-specific risk of fetal loss post second trimester amniocentesis: analysis of 5043 cases. Prenat Diagn 2007; 27: 180-183.
28. Towner D, Currier RJ, Lorey FW, Cunningham GC, Greve LC. Miscarriage risk from amniocentesis performed for abnormal maternal serum screening. Am J Obstet Gynecol 2007; 196: 608.e1-5.
29. Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year experience. Obstet Gynecol 2008; 111: 589-595.
30. Tabor A, Vestergaard CH, Lidegaard O. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 2009; 34: 19-24.
31. Zhang L, Zhang XH, Liang MY, Ren MH. Prenatal cytogenetic diagnosis study of 2782 cases of high-risk pregnant women. Chin Med J (Engl) 2010; 123: 423-430.
32. Kalogiannidis I, Prapa S, Dagklis T, Karkanaki A, Petousis S, Prapas Y, Prapas N. Amniocentesis-related adverse outcomes according to placental location and risk factors for fetal loss after midtrimester amniocentesis. Clin Exp Obstet Gynecol 2011; 38: 239-242.
33. Pitukkijronnakorn S, Promsonthi P, Panburana P, Udomsubpayakul U, Chittacharoen A. Fetal loss associated with second trimester amniocentesis. Arch Gynecol Obstet 2011; 284: 793-797.
34. Corrado F, Cannata ML, La Galia T, Magliarditi M, Imbruglia L, D'anna R, Carlo Stella N. Pregnancy outcome following mid-trimester amniocentesis. J Obstet Gynaecol 2012; 32: 117-119.
35. Dhaifalah I, Zapletalova J. Safety and risks associated with screening for chromosomal abnormalities during pregnancy. Ceska Gynekol 2012; 77: 236-241.
36. Brambati B, Tului L, Camurri L, Guercilena S. Early second trimester (13 to 20 weeks) transabdominal chorionic villus sampling (TA-CVS): a safe and alternative method for both high and low risk populations. Prenat Diagn 2002; 22: 907-913.
37. Papp C, Beke A, Mezei G, Tóth-Pál E, Papp Z. Chorionic villus sampling: a 15-year experience. Fetal Diagn Ther 2002; 17: 218-227.
38. Lau KT, Leung YT, Fung YT, Chan LW, Sahota DS, Leung NT. Outcome of 1,355 consecutive transabdominal chorionic villus samplings in 1,351 patients. Chin Med J (Engl) 2005; 118: 1675-1681.
39. Odibo AO, Dicke JM, Gray DL, Oberle B, Stamilio DM, Macones GA, Crane JP. Evaluating the rate and risk factors for fetal loss after chorionic villus sampling. Obstet Gynecol 2008; 112: 813-819.
40. Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH. Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling. Prenat Diagn 2011; 31: 38-45.
41. Flather MD, Farkouh ME, Pogue JM, Yusuf S. Strengths and limitations of meta-analysis: larger studies may bemore reliable. Control Clin Trials 1997; 18: 568-579.
42. Bartolucci A, Hillegass W. Overview, Strengths, and Limitations of Systematic Reviews and Meta-Analyses. In Evidence-Based Practice: Toward Optimizing Clinical Outcomes, Chiappelli F, Caldeira Brant XM, Neagos N, Oluwadara O, Ramchandani M (eds), 17-33. DOI: 10.1007/978-3-642-05025-1-2, © Springer-Verlag Berlin Heidelberg 2010.
43. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005; 192: 1005-1021.
44. Bilardo CM, Müller MA, Pajkrt E, Clur SA, van Zalen MM, Bijlsma EK. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 2007; 30: 11-18.
45. Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH. Screening for adverse pregnancy outcome by ductus venosus Doppler at 11- 13 + 6 weeks of gestation. Obstet Gynecol 2008; 112: 598-605.
46. Spencer K, Cowans NJ, Avgidou K, Nicolaides KH. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 2006; 28: 637-643.
47. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Nørgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986; 1: 1287-1293.
48. Seeds JW. Diagnostic mid trimester amniocentesis: how safe? Am J Obstet Gynecol 2004; 191: 607-615.
49. Nicolaides KH, Brizot M, Patel F, Snijders R. Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10-13 weeks' gestation. Lancet 1994; 344: 435-439.
50. Sundberg K, Bang J, Smidt-Jensen S, Brocks V, Lundsteen C, Parner J, Keiding N, Philip J. Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Lancet 1997; 350: 697-703.
51. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 2010; 27: 1-7.
52. Wijnberger LDE, van der Schouw YT, Christiaens GCML. Learning in medicine: chorionic villus sampling. Prenat Diagn 2000; 20: 241-246.
53. Blessed WB, Lacoste H, Welch RA. Obstetrician-gynecologists performing genetic amniocentesis may be misleading themselves and their patients. Am J Obstet Gynecol 2001; 184: 1340-1342.
54. NHS Fetal Anomaly Screening Programme. Screening for Down's syndrome: UK NSC Policy recommendations 2011-2014 Model of Best Practice. Department of Health, 2011.
55. Oxman AD, Clarke MJ, Stewart LA. From science to practice. Meta-analyses using individual patient data are needed. JAMA 1995; 274: 845-846.
56. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010; 340: c221.
57. NHS Fetal Anomaly Screening Programme. Down's Syndrome Screening Quality Assurance Support Service (DQASS): DQASS working structure, November 2012. Accessed on http://fetalanomaly.screening.nhs.uk/dqasspublications [Accessed 3 March 2014].
58. Williams SM, Parry BR, Schlup MM. Quality control: an application of the cusum. BMJ 1992; 304: 1359-1361.
59. Lim TO, Soraya A, Ding LM, Morad Z. Assessing doctors' competence: application of CUSUM technique in monitoring doctors' performance. Int J Qual Health Care 2002; 14: 251-258.
60. Young A, Miller JP, Azarow K. Establishing learning curves for surgical residents using Cumulative Summation (CUSUM) Analysis. Curr Surg 2005; 62: 330-334.